Actively Recruiting
Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
Led by Chinese Academy of Sciences · Updated on 2025-09-12
400
Participants Needed
19
Research Sites
104 weeks
Total Duration
On this page
Sponsors
C
Chinese Academy of Sciences
Lead Sponsor
P
Peking Union Medical College Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Hepatocellular carcinoma (HCC) is a common malignancy in China with a high mortality rate. Its early recurrence and long-term prognosis are closely associated with tumor aggressiveness. Microvascular invasion (MVI), defined as the presence of tumor cells within small branches of the portal or hepatic veins, is a key indicator of malignant biological behavior in HCC. Clinically, MVI is strongly correlated with postoperative early recurrence and serves as an important factor in determining surgical margin extension, adjuvant therapy, and postoperative management strategies. At present, definitive diagnosis of MVI still relies on postoperative pathological examination, and stable, effective preoperative assessment methods are lacking. Although some studies have attempted to predict MVI using preoperative imaging features, their clinical translation remains limited by poor generalizability, weak interpretability, and insufficient cross-center adaptability. This study aims to leverage multiphase preoperative CT imaging, artificial intelligence techniques, and clinical prior knowledge to develop a high-performance, generalizable, and interpretable computer-aided diagnostic system for preoperative prediction of HCC-MVI. An observational, prospective evaluation will be conducted to assess system performance and to facilitate the clinical translation of intelligent diagnostic technologies in real-world practice.
CONDITIONS
Official Title
Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 69; 18 years
- Confirmed diagnosis of hepatocellular carcinoma (HCC) based on Chinese Clinical Practice Guidelines for Primary Liver Cancer
- Eligible for liver surgery (hepatic resection or liver transplantation) as per Chinese Clinical Practice Guidelines for Cancer, including stages Ia, Ib, and IIa
- Underwent preoperative imaging within 1 month before surgery
- Histopathological evaluation available with documented microvascular invasion (MVI) status
You will not qualify if you...
- History of prior antitumor treatment including surgery, transarterial chemoembolization (TACE), radiofrequency ablation (RFA), systemic therapy, or other preoperative interventions
- Major vascular invasion, bile duct invasion or thrombosis, extrahepatic metastasis, or lymph node involvement
- Diffuse hepatocellular carcinoma or tumor rupture with bleeding
- Missing key data required for primary analysis
- Poor quality imaging preventing reliable analysis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 19 locations
1
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, China
Actively Recruiting
2
Guangdong Provincial Hospital of Traditional Chinese Medicine
Guangzhou, Guangdong, China
Actively Recruiting
3
Zhujiang Hospital
Guangzhou, Guangdong, China
Actively Recruiting
4
Fifth Affiliated Hospital, Sun Yat-Sen University
Zhuhai, Guangdong, China
Actively Recruiting
5
Zhuhai People's Hospital
Zhuhai, Guangdong, China
Actively Recruiting
6
First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
Actively Recruiting
7
Guizhou Provincial People's Hospital
Guiyang, Guizhou, China
Actively Recruiting
8
Henan Provincial People's Hospital
Zhengzhou, Henan, China
Actively Recruiting
9
Shengjing Hospital
Shenyang, Liaoning, China
Actively Recruiting
10
West China Hospital
Chengdu, Sichuan, China
Actively Recruiting
11
Dazhou Central Hospital
Dazhou, Sichuan, China
Actively Recruiting
12
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Actively Recruiting
13
The First People's Hospital of Yunnan Province
Kunming, Yunnan, China
Actively Recruiting
14
Yunnan Cancer Hospital
Kunming, Yunnan, China
Actively Recruiting
15
First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Actively Recruiting
16
Beijing Tsinghua Changgeng Hospital
Beijing, China
Actively Recruiting
17
Beijing YouAn Hospital
Beijing, China
Actively Recruiting
18
Peking Union Medical College Hospital
Beijing, China
Actively Recruiting
19
Eastern Hepatobiliary Surgery Hospital
Shanghai, China
Actively Recruiting
Research Team
D
Di Dong, Ph.D.
CONTACT
M
Mengjie Fang, Ph.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
19
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here